Moxonidine (CAS 75438-57-2) – Antihypertensive API

Moxonidine (CAS 75438-57-2) is a high-purity pharmaceutical API, a second-generation central-acting antihypertensive with high selectivity for I1 imidazoline receptors. Its imidazoline derivative structure ensures 33-fold higher affinity for I1 receptors than α2-adrenergic receptors, reducing central sympathetic outflow to lower peripheral vascular resistance and blood pressure. Unlike first-generation central 降压药，it minimizes sedation and dry mouth, with a more favorable tolerability profile.

As a white crystalline powder with moderate lipophilicity and 88% oral bioavailability, it suits oral tablets and capsules. It meets the core needs of cardiovascular drug manufacturers, hypertension therapy developers, and clinical supply chains. Widely used for mild to moderate essential hypertension, it is especially suitable for patients with metabolic syndrome like diabetes or obesity due to its insulin resistance-improving effect. Produced under strict GMP standards, each batch undergoes rigorous purity, stability, and receptor selectivity testing to meet international pharmacopoeia requirements, ensuring consistent clinical efficacy.